Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05728372 | 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT05828277 | A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients | withdrawn | Phase 1 | 0 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Sep 26, 2023 |
| NCT05284214 | Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors(SALIENT) | withdrawn | Phase 2 | 0 | Partner Therapeutics, Inc.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT01971489 | Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05169151 | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT05038384 | Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT05222165 | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations(NEWEL) | withdrawn | Phase 1 / Phase 2 | 0 | Helsinn Healthcare SAINDUSTRY | 3 | Feb 23, 2023 | clinicaltrials |
| NCT03338881 | A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies | withdrawn | Phase 1 | 0 | Calithera Biosciences, IncINDUSTRY | 0 | Feb 8, 2023 | clinicaltrials |
| NCT03359733 | A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor | withdrawn | Phase 1 | 0 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03789773 | Holographic Mm-Wave Imaging in Patients Undergoing Radiation Therapy | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05381935 | A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Elpiscience Biopharma, Ltd.INDUSTRY | 0 | Jan 31, 2023 | clinicaltrials |
| NCT05060276 | Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors | withdrawn | Phase 1 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Jan 26, 2023 | clinicaltrials |
| NCT04797468 | A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor | withdrawn | Phase 1 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | Dec 27, 2022 | clinicaltrials |
| NCT04316169 | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT03906643 | HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies | withdrawn | Phase 1 | 0 | Herbert LyerlyOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05469490 | Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Luke, Jason, MDOTHER | 0 | Sep 30, 2022 | clinicaltrials |
| NCT04878484 | Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Athenex, Inc.INDUSTRY | 0 | Sep 2, 2022 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 | clinicaltrials |
| NCT03427320 | Imaging of Advanced Tumours Using [131]I-IAZA | withdrawn | Phase 1 / Phase 2 | 0 | University of AlbertaOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT04891718 | CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | withdrawn | Early Phase 1 | 0 | Presage BiosciencesINDUSTRY | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05010096 | BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT05165849 | A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Zhejiang Genfleet Therapeutics Co., Ltd.INDUSTRY | 0 | May 20, 2022 | clinicaltrials |
| NCT04803630 | Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04809012 | Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Mar 25, 2022 | clinicaltrials |
| NCT03868423 | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers | withdrawn | Phase 2 | 0 | Sameek RoychowdhuryOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05242926 | Absorption and Excretion of Oral Docetaxel | withdrawn | Phase 1 | 0 | Modra PharmaceuticalsINDUSTRY | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT05084456 | Oral Docetaxel in Patients With Normal or Impaired Liver Function | withdrawn | Phase 1 | 0 | Modra PharmaceuticalsINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT00900120 | Collecting and Storing Blood Samples From Patients With Cancer | withdrawn | — | 0 | University of Medicine and Dentistry of New JerseyOTHER | 0 | Sep 21, 2021 | clinicaltrials |
| NCT02896049 | Celsius TCS Hyperthermia System PMCF Trial | withdrawn | — | 0 | Celsius42 GmbHINDUSTRY | 0 | Jul 27, 2021 | clinicaltrials |
| NCT04655183 | Study of M4344 in Combination With Niraparib | withdrawn | Phase 1 / Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Jun 30, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03706274 | PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors | withdrawn | Phase 1 | 0 | CytomX TherapeuticsINDUSTRY | 1 | May 5, 2021 | clinicaltrials |
| NCT03728205 | Yoga for Solid Tumor | withdrawn | N/A | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04455958 | Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Apr 26, 2021 | clinicaltrials |
| NCT03443622 | Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors | withdrawn | Phase 1 | 0 | SupremeCure Pharma Inc.INDUSTRY | 0 | Oct 22, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2020 | clinicaltrials |
| NCT00753740 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | withdrawn | Phase 2 | 0 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 12, 2020 | clinicaltrials |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 0 | Apr 1, 2020 | clinicaltrials |
| NCT02277561 | Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery | withdrawn | N/A | 0 | Albert Einstein College of MedicineOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02800889 | Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer | withdrawn | Phase 1 | 0 | CTI BioPharmaINDUSTRY | 1 | Jan 29, 2020 | clinicaltrials |
| NCT02691780 | Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors | withdrawn | N/A | 0 | Samsung Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT02368106 | Prospective Patient Registry for Radiation Oncology Techniques and Quality(GCC 1490) | withdrawn | — | 0 | University of Maryland, BaltimoreOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02747537 | Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Oct 10, 2023source: clinicaltrials